Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC

Forensic Science International

Volumn 265, Issue , 2016, Pages 121-124

  Klavž, Janez ^a   Gorenjak, Maksimiljan ^a   Marinšek, Martin ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

Cathinone derivative; GC MS; Suicide; Synthetic cannabinoids

Indexed keywords

4 CHLOROMETHCATHINONE; AB CHMINACA; AB FUBINACA; ALPHA PYRROLIDINOHEXIOPHENONE; CANNABINOID; CATHINONE; DIAZEPAM; FLUOXETINE; GLUCOSE; METHANOL; NALOXONE; QUETIAPINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ALKALOID; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; CASE REPORT; COMATOSE PATIENT; DEHYDRATION; DRUG IDENTIFICATION; DRUG INTOXICATION; DRUG SCREENING; GLASGOW COMA SCALE; HUMAN; INTENSIVE CARE UNIT; LIQUID LIQUID EXTRACTION; MALE; MASS FRAGMENTOGRAPHY; MYDRIASIS; PRIORITY JOURNAL; SINUS TACHYCARDIA; SLOVENIA; SOMNOLENCE; STIMULUS RESPONSE; STOMACH CONTENT; SUICIDE ATTEMPT; URINALYSIS; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; FORENSIC TOXICOLOGY;

ADULT; ALKALOIDS; CANNABINOIDS; DIAGNOSIS, DIFFERENTIAL; FORENSIC TOXICOLOGY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; POISONING; PSYCHOTROPIC DRUGS; SUICIDE, ATTEMPTED;

EID: 84957989577     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2016.01.018     Document Type: Article

References (19)

1. EMCDDA European Drug Report 2015: Trends and Developments, Euro Surveill, doi: 0.2810/084165, Available from 〈http://www.emcdda.europa.eu/〉.
2. Cottencin O., Rolland B., Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr. Pharm. Des. 2014, 20:4106-4111.
3. Wurita A., Hasegawa K., Minakata K., Gonmori K., Nozawa H., Yamagishi I., et al. Identification and quantification of metabolites of AB-CHMINACA in a urine specimen of an abuser. Leg. Med. 2015, 10.1016/j.legalmed.2015.07.011.
4. Uchiyama N., Matsuda S., Wakana D., Kikura-Hanajiri R., Goda Y. New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol. 2013, 31:93-100.
5. Banister S.D., Moir M., Stuart J., Kevin R.C., Wood K.E., Longworth M., et al. Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem. Neurosci. 2015, 6:1546-1559.
6. Trecki J., Gerona R.R., Schwartz M.D. Synthetic cannabinoid-related illnesses and deaths. N. Engl. J. Med. 2015, 373:103-107.
7. E. Seeger, Pykrolidino ketones. Patent US; 1967/3314970 A.
8. Sauer C., Peters F.T., Haas C., Meyer M.R., Fritschi G., Maurer H.H. New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass. Spectrom. 2009, 44:952-964.
9. Taschwer M., Weiss J.A., Kunert O., Schmid M.G. Analysis and characterization of the novel psychoactive drug 4-chloromethcathinone (clephedrone). Forensic Sci. Int. 2014, 244:e56-e59.
10. Valente M.J., Guedes de Pinho P., de Lourdes Bastos M., Carvalho F., Carvalho M. Khat and synthetic cathinones: a review. Arch. Toxicol. 2014, 88:15-45.
11. James D., Adams R.D., Spears R., Cooper G., Lupton D.J., Thompson J.P., et al. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg. Med. J. 2011, 28:686-689.
12. Murray B.L., Murphy C.M., Beuhler M.C. Death following recreational use of designer drug "bath salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 2012, 8:69-75.
13. Hermanns-Clausen M., Kneisel S., Szabo B., Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013, 108:534-544.
14. Celofiga A., Koprivsek J., Klavz J. Use of synthetic cannabinoids in patients with psychotic disorders: case series. J. Dual Diagn. 2014, 10:168-173.
15. Available from (accessed 5.2.16). 〈http://www.toxinz.com/.
16. China Food and Drug Administration, Available from 〈〉 (in Chinese), 27 September 2015 (accessed 8.10.15). http://www.sfda.gov.cn/.
17. Castaneto M.S., Gorelick D.A., Desrosiers N.A., Hartman R.L., Pirard S., Huestis M.A. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014, 144:12-41.
18. Hasegawa K., Wurita A., Minakata K., Gonmori K., Nozawa H., Yamagishi I., et al. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. Forensic Toxicol. 2015, 33:380-387.
19. Hasegawa K., Wurita A., Minakata K., Gonmori K., Nozawa H., Yamagishi I., et al. Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms. Forensic Toxicol. 2015, 33:45-53.